A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD
Public ClinicalTrials.gov record NCT06075095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared With BGF Delivered by MDI HFA in Participants With Chronic Obstructive Pulmonary Disease
Study identification
- NCT ID
- NCT06075095
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 297 participants
Conditions and interventions
Conditions
Interventions
- BGF MDI HFO 320/14.4/9.6μg Drug
- BGF MDI HFA 320/14.4/9.6 μg Drug
- Placebo MDI HFA Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 10, 2024
- Primary completion
- Aug 11, 2025
- Completion
- Aug 11, 2025
- Last update posted
- Aug 26, 2025
2024 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Sheffield | Alabama | 35660 | — |
| Research Site | Clearwater | Florida | 33765 | — |
| Research Site | Gainesville | Florida | 32605 | — |
| Research Site | Miami | Florida | 33175 | — |
| Research Site | Orlando | Florida | 32825 | — |
| Research Site | Tampa | Florida | 33606 | — |
| Research Site | Rincon | Georgia | 31326 | — |
| Research Site | Chicago | Illinois | 60607 | — |
| Research Site | Saint Charles | Missouri | 63301 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research Site | The Bronx | New York | 10455 | — |
| Research Site | Raleigh | North Carolina | 27607 | — |
| Research Site | Dublin | Ohio | 43016 | — |
| Research Site | Medford | Oregon | 97504 | — |
| Research Site | Portland | Oregon | 97202 | — |
| Research Site | Philadelphia | Pennsylvania | 19114 | — |
| Research Site | Gaffney | South Carolina | 29340 | — |
| Research Site | Boerne | Texas | 78006 | — |
| Research Site | El Paso | Texas | 79912 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06075095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06075095 live on ClinicalTrials.gov.